Deciphering the Pathophysiological Mechanisms Underpinning Myoclonus Dystonia Using Pluripotent Stem Cell-Derived Cellular Models

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Sep 27

PMID 39329704

Authors

Zongze Li

Laura Abram

Kathryn J Peall

Affiliations

Soon will be listed here.

Abstract

Dystonia is a movement disorder with an estimated prevalence of 1.2% and is characterised by involuntary muscle contractions leading to abnormal postures and pain. Only symptomatic treatments are available with no disease-modifying or curative therapy, in large part due to the limited understanding of the underlying pathophysiology. However, the inherited monogenic forms of dystonia provide an opportunity for the development of disease models to examine these mechanisms. Myoclonus Dystonia, caused by mutations encoding the ε-sarcoglycan protein, represents one of now >50 monogenic forms. Previous research has implicated the involvement of the basal ganglia-cerebello-thalamo-cortical circuit in dystonia pathogenesis, but further work is needed to understand the specific molecular and cellular mechanisms. Pluripotent stem cell technology enables a patient-derived disease modelling platform harbouring disease-causing mutations. In this review, we discuss the current understanding of the aetiology of Myoclonus Dystonia, recent advances in producing distinct neuronal types from pluripotent stem cells, and their application in modelling Myoclonus Dystonia in vitro. Future research employing pluripotent stem cell-derived cellular models is crucial to elucidate how distinct neuronal types may contribute to dystonia and how disruption to neuronal function can give rise to dystonic disorders.

References

Hess C, Saunders-Pullman R . Movement disorders and alcohol misuse. Addict Biol. 2006; 11(2):117-25. DOI: 10.1111/j.1369-1600.2006.00017.x. View

Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

Washburn S, Fremont R, Moreno-Escobar M, Angueyra C, Khodakhah K . Acute cerebellar knockdown of reproduces salient features of myoclonus-dystonia (DYT11) in mice. Elife. 2019; 8. PMC: 6959989. DOI: 10.7554/eLife.52101. View

Asmus F, Salih F, Elisabeth Hjermind L, Ostergaard K, Munz M, Kuhn A . Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol. 2005; 58(5):792-7. DOI: 10.1002/ana.20661. View

Menozzi E, Balint B, Latorre A, Valente E, Rothwell J, Bhatia K . Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction. Mov Disord. 2019; 34(11):1588-1601. DOI: 10.1002/mds.27822. View

Kim T, Piao J, Koo S, Kriks S, Chung S, Betel D . Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021; 28(2):343-355.e5. PMC: 8006469. DOI: 10.1016/j.stem.2021.01.005. View

Wang X, Yu X . Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data. Neurosurg Rev. 2020; 44(1):451-462. DOI: 10.1007/s10143-019-01233-x. View

Holt K, Campbell K . Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem. 1998; 273(52):34667-70. DOI: 10.1074/jbc.273.52.34667. View

Yokoi F, Dang M, Yang G, Li J, Doroodchi A, Zhou T . Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models. Behav Brain Res. 2011; 227(1):12-20. PMC: 3242862. DOI: 10.1016/j.bbr.2011.10.024. View

10.

Tshilenge K, Bons J, Aguirre C, Geronimo-Olvera C, Shah S, Rose J . Proteomic analysis of X-linked dystonia parkinsonism disease striatal neurons reveals altered RNA metabolism and splicing. Neurobiol Dis. 2023; 190:106367. PMC: 11103251. DOI: 10.1016/j.nbd.2023.106367. View

11.

Golas M, Sander B . Use of human stem cells in Huntington disease modeling and translational research. Exp Neurol. 2016; 278:76-90. DOI: 10.1016/j.expneurol.2016.01.021. View

12.

Lee J, Lyoo C, Lee M . A patient with genetically confirmed myoclonus-dystonia responded to anticholinergic treatment and improved spontaneously. J Clin Neurol. 2012; 7(4):231-2. PMC: 3259499. DOI: 10.3988/jcn.2011.7.4.231. View

13.

Hashimoto Y, Kuniishi H, Sakai K, Fukushima Y, Du X, Yamashiro K . Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy. Prog Neurobiol. 2022; 216:102288. DOI: 10.1016/j.pneurobio.2022.102288. View

14.

Calderon D, Fremont R, Kraenzlin F, Khodakhah K . The neural substrates of rapid-onset Dystonia-Parkinsonism. Nat Neurosci. 2011; 14(3):357-65. PMC: 3430603. DOI: 10.1038/nn.2753. View

15.

Nolbrant S, Heuer A, Parmar M, Kirkeby A . Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat Protoc. 2017; 12(9):1962-1979. DOI: 10.1038/nprot.2017.078. View

16.

Martella G, Maltese M, Nistico R, Schirinzi T, Madeo G, Sciamanna G . Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. Neurobiol Dis. 2014; 65:124-32. DOI: 10.1016/j.nbd.2014.01.016. View

17.

Starr P, Rau G, Davis V, Marks Jr W, Ostrem J, Simmons D . Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque. J Neurophysiol. 2005; 93(6):3165-76. DOI: 10.1152/jn.00971.2004. View

18.

Ho S, Hartley B, Tcw J, Beaumont M, Stafford K, Slesinger P . Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells. Methods. 2015; 101:113-24. PMC: 4860098. DOI: 10.1016/j.ymeth.2015.11.019. View

19.

Tao O, Shimazaki T, Okada Y, Naka H, Kohda K, Yuzaki M . Efficient generation of mature cerebellar Purkinje cells from mouse embryonic stem cells. J Neurosci Res. 2009; 88(2):234-47. DOI: 10.1002/jnr.22208. View

20.

Luciano A, Jinnah H, Pfeiffer R, Truong D, Nance M, Ledoux M . Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014; 20(12):1423-6. PMC: 4254189. DOI: 10.1016/j.parkreldis.2014.09.029. View